EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Corey Iacono | Mar 14, 2023

In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements
Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

by Corey Iacono | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides  
Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Riley Nolan | Oct 11, 2022

A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform

A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform

by Riley Nolan | Jun 7, 2022

A novel SARS-CoV-2 T cell targeting, peptide-based vaccine candidate designed using the iVAX platform
« Older Entries

Recent Posts

  • From Kyoto, with Love
  • EpiVax Turns 25!
  • Happy Valentine’s Day! And don’t argue with Chatbots!
  • ISPRI in silico Toolkit in the Literature
  • Platform shoes, Bellbottoms and #CrueltyFreeFDA!

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562